Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives $95.14 Consensus PT from Brokerages

Key Points

• Abivax SA Sponsored ADR (NASDAQ:ABVX) has received an average rating of "Buy" from nine brokerages, with one analyst issuing a "strong buy" rating, suggesting positive sentiment among analysts.
• Recent brokerage reports have seen target price increases for ABVX, with Guggenheim raising it to $101.00 and Lifesci Capital also targeting $101.00.
• Shares of Abivax have fluctuated significantly, reaching a one-year high of $92.91 and currently showing a slight drop of 1.8% at $87.63.

Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) has been assigned an average rating of "Buy" from the nine ratings firms that are currently covering the company, MarketBeat reports. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $99.4286.

A number of analysts recently commented on the company. Wall Street Zen upgraded Abivax from a "sell" rating to a "hold" rating in a research report on Saturday. Lifesci Capital upped their price target on Abivax from $45.00 to $101.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 23rd. Morgan Stanley raised their price objective on Abivax from $71.00 to $101.00 and gave the stock an "overweight" rating in a research note on Friday. Leerink Partners set a $74.00 price objective on Abivax and gave the stock an "outperform" rating in a research note on Wednesday, July 23rd. Finally, Piper Sandler raised their price objective on Abivax from $70.00 to $112.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 29th.

Abivax Price Performance

Abivax stock traded up $1.86 during mid-day trading on Thursday, reaching $85.87. 858,681 shares of the stock traded hands, compared to its average volume of 1,152,597. The company has a quick ratio of 0.77, a current ratio of 0.77 and a debt-to-equity ratio of 1.29. Abivax has a 12-month low of $4.77 and a 12-month high of $92.91. The business's 50-day moving average is $61.28 and its 200-day moving average is $25.75.

Abivax (NASDAQ:ABVX - Get Free Report) last posted its quarterly earnings data on Monday, September 8th. The company reported ($0.86) EPS for the quarter, beating analysts' consensus estimates of ($0.90) by $0.04. Equities research analysts anticipate that Abivax will post -2.83 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Two Sigma Investments LP bought a new position in shares of Abivax in the fourth quarter worth about $144,000. GAMMA Investing LLC raised its stake in shares of Abivax by 373.6% in the first quarter. GAMMA Investing LLC now owns 18,831 shares of the company's stock worth $118,000 after buying an additional 14,855 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Abivax by 47.5% in the fourth quarter. BNP Paribas Financial Markets now owns 19,244 shares of the company's stock worth $141,000 after buying an additional 6,200 shares during the period. Millennium Management LLC boosted its stake in shares of Abivax by 44.2% in the fourth quarter. Millennium Management LLC now owns 931,179 shares of the company's stock worth $6,816,000 after acquiring an additional 285,542 shares during the period. Finally, Octagon Capital Advisors LP bought a new position in shares of Abivax in the first quarter worth about $7,688,000. Institutional investors own 47.91% of the company's stock.

Abivax Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.